Femasys Inc 2025年季度报告

OR Commission file number:001-40492.Femasys Inc. (Exact Name of Registrant as Specified in its Charter) 3950 Johns Creek Court,Suite 100Suwanee,GA(Address of principal executive offices) (Registrant’s telephone number, including area code) (Former name, former address and former fiscal year, if changedsince last report) Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☑No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller Non-accelerated filer☑Smaller reporting company☑Emerging growth company☑ Condensed Notes to Financial Statements (unaudited)Management’s Discussion and Analysis of Financial Condition and Results of Operations Quantitative and Qualitative Disclosures About Market RiskControls and Procedures Part II. Other InformationLegal ProceedingsItem 1ARisk Factors ExhibitsSIGNATURES 2 “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions,although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, FemBloc® permanent birth control, if approved for sale, approved products and fund our operations;• our ability to pay our convertible notes due November 2025, if not converted into common stock; • our ability to successfully grow sales of FemaSeed® intratubal insemination; • estimates regarding the total addressable market for our products and product candidate; • competitive companies and technologies in our industry; • our business model and strategic plans for our products, product candidate, technologies and business, including our implementation • commercial success and market acceptance of our products and product candidate; • our ability to achieve and maintain adequate levels of coverage or reimbursement for FemBloc or any future product candidates, andour products we seek to commercialize; • our ability to accurately forecast customer demand for our products and product candidate, and manage our inventory;• our ability to build, manage, and maintain our direct sales and marketing organization, and to market and sell our FemaSeed artificialinsemination product, FemBloc permanent birth control system (if approved for sale), and women-specific medical product solutionsin markets in and outside of the United States;• our ability to establish, maintain, grow or increase sales and revenues;• our expectations about market trends; Common stock — Balance at March 31, 2025 THREE MONTHSENDED MARCH 31,Balance at December 31,21,774,604$21,775117,223$(60,000)$2,787,137$123,985,306$(108,381,629)$18,352,5Issuance of common stockin connection with at-the-market offering, netof issuance costs441,966442———776,488—Share-based compensation—————77,585—Expiration of warrant(155,299)155,299——————(3,599,510)(3,599,5Balance at March 31, 202422,216,570$22,217117,223$(60,000)$2,631,838$124,994,678$(111,981,139)$15,607,5The accompanying notes are an integral part of these condensed unaudited financial statements.8 Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities:Depreciation77,682Amortization7,171Amortization of right-of-use assets132,207Accounts receivable reserve(5,000) Cash flows from investing activities:Acquisition of patents—Purchases of property and equipment(96,605) Proceeds from at-the-market sales of common stockIssuance costs for at-the-market sales of common stock Net cash provided by financing activities5,230,266Net change in cash and cash equivalents368,447(3,880,109)Cash and cash equivalents:Beginning of period3,451,76121,716,077 Supplemental cash flow informationNon-cash investing and financing activities: Property and equipment costs included in accounts payable and accrued expense$22,072Acquisition of patents included in accounts payable—Deferred offering costs reclassified to additional paid-in-capital8,369The accompanying notes are an integral part of these condensed unaudited financial statements. Organization and Nature of BusinessFemasys Inc. (the Company or Femasys) was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, an endocervical tissue sampler for cervical cancer diagnosis, is U.S. FDA-cleared and approved in Europe, UK, Canada and Israel.FemBloc® permanent birth control is a revolutionary first-in-class non-surgical solution, that involves the minimally-invasiveplacement of a patented delivery system for precise delivery of our proprietary synthetic tissue adhesive (blended polymer) into both reported risks that include infection, minor or major bleeding, injury to nearby organs, anesthesia-related events, and even